Twentyeight-Seven Therapeutics
Cambridge
About Twentyeight-Seven Therapeutics
Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $80.0M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2019)
- Website: twentyeight-seven.com
- Phone: 617-331-7523
Industries & Categories
Biotechnology, Developer Platform, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/twentyeight-seven-therapeutics-39679 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.